The American Association of Kidney Patients’ (AAKP) is the largest kidney patient organization in America. We have a proud 50-year history of advocating for increased patient care choice and access to the timely disease education and the diagnostics, biologics and devices that empower patients to remain fully engaged in life and society. We are unfailing optimists in our belief that science, innovation, and technology can save lives and improve patient outcomes – we know, because AAKP is led by patients whose lives have been saved by disease education and medical advancements. At AAKP, being patient-centric is inherent, not a mission statement.
The AAKP national team is comprised of experienced policy, business and non-profit professionals who happen to have kidney disease. Our national Board of Directors and our National and Global Patient Ambassadors represent the full range of kidney diseases, including rare/genetic diseases, and as a diverse team of enthusiastic advocates and educators, they represent the full diversity of America and the communities most impacted kidney diseases. We are united in our shared concern kidney diseases must be detected early and accurately, progression must be delayed, and patient care choice must include all new treatments and innovations – including pre-emptive transplantation and all home care options.
We understand the intricate world of policy, regulation, legislation, and reimbursement issues. We know how these mechanisms determine ongoing progress in the field of kidney disease medicine or a default to unimaginative status quo healthcare. With our expansive databases and data collection technologies, we are experts in collecting the unique patient preference insights (PPI), patient reported outcomes (PRO) and real-world evidence (RWE) that leaders in diagnostic, drug and device innovation need to develop solutions that are informed by patient life experiences.
AAKP is committed to adding high value to industry partners through substantive engagement and opportunities for industry to support the AAKP mission of helping reduce the devasting impacts of kidney diseases and to save lives. As a non-profit, non-partisan with a Platinum rating from GuideStar Charities, we use a national strategy to intelligently incorporate our dedicated legions of volunteer patient experts and smart business technologies – so we keep our overhead low, operate, and operate at a fraction of the cost of other national advocacy organizations whose comparatively massive overheads demand constant fundraising and diffuse impact and effectiveness. Our integrated national strategy has made us a well-known and highly respected advocate for our fellow kidney patients – and a vital partner for industry partners seeking to advance innovations and care treatments for the fellow patients we are honored to represent.
Simply stated, our annual corporate memberships allow our industry partners to demonstrate their commitment to helping to improve the life of patients. Based on the results we achieve and the level of genuine patient engagement the AAKP brand generates, we believe our Global and National Corporate Memberships, at any level, are among the best investments your company can make.
Global Membership Opportunities
Global Membership with AAKP is a unique opportunity to directly support the organization and AAKP’s Decade of the Kidney™ – a 10-year initiative announced in 2019, upon the signing of the ground-breaking and bipartisan Advancing American Kidney Health federal policy and the start of our 50th Anniversary year. During this decade, we believe kidney patients will take a more central role, alongside our allies, to accelerate kidney medicine away from tired status quo of kidney care medicine.
We are committed to working with researchers, clinical trial experts and the private sector to reshape the future for patients and health outcomes. Help us – and let us help your company – toward a future defined by greater patient treatment choice; new, targeted therapies and diagnostics to detect, inhibit and better manage kidney diseases and prevent kidney failure; and greater access to life-sustaining devices and organs including artificial wearable and implantable kidneys. AAKP is convinced that an organized, global patient consumer voice, through a coordinated patient and professional consortium, will accelerate research and policies that speed innovation, increase market demand and lead to more favorable payment and reimbursement decisions to support the entry of new, life sustaining products into the healthcare marketplace.
Contact Diana Clynes, AAKP Executive Director at firstname.lastname@example.org or (813) 400-2391 for AAKP Global Kidney Health Council Membership Opportunities.
National Membership Opportunities
Contact Erin Kahle, AAKP Director of Stakeholder Operations at email@example.com or (813) 400-2393 for AAKP National Membership Opportunities.
At Amgen, we are both students and teachers of biology. Amgen brings together many of the very best scholars, scientists and professionals. We are united steadfastly focused on a single mission – helping patients. It’s what drives us to push the boundaries of science, to transform medicine. We dedicate our days to turning the tide on serious, life-interrupting illnesses – to make a positive difference for our families, our friends and our communities. Before we attack a disease, our researchers study it closely – watching the body’s most subtle changes, exploring its mechanisms in new ways to better understand the causes of disease. Over decades, this has given us deep expertise in biotechnology, mastering the complex art and science of engineering and manufacturing medicines through the use of living cells. Now, Amgen is at the forefront of a new biocentury. Learn more about Amgen, Inc.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Learn more about AstraZeneca www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care. Learn more about Baxter International Inc.
Mallinckrodt Pharmaceuticals is a specialty pharmaceutical company focused on their mission: Managing Complexity. Improving Lives. They provide medicines to address unmet patient needs, stemming from 150 years of using their unique strengths, experience and expertise to help improve people’s lives. Discover how their rich history of innovation and patient-centered solutions has helped influence their vision for the future. Learn more about Mallinckrodt.
When Otsuka saw a need for clinical expertise and research in the nephrology space, we decided to lead the way. For more than 20 years, we have been bringing our research and expertise to this therapeutic area. We have focused on developing novel drugs in areas of unmet need, such as autosomal dominant polycystic kidney disease and hyponatremia, that have changed the treatment landscape. Our long-term perseverance has led to major breakthroughs, giving patients renewed hope and clinicians more options than ever before. Learn more about Otsuka America Pharmaceutical. Inc.
Aurinia exists to make a difference. From the earliest days of the company, we’ve seen the potential in applying a creative, thoughtful and responsible approach to developing and commercializing therapies with a goal of changing the course for patients in disease areas that have been historically challenging to address. Our strategy leverages the skills and knowledge of our team’s extensive clinical experience in the treatment of renal diseases and autoimmune diseases, and our progress has been guided by leaders with a bold vision and expertise in principled drug development and commercialization. Learn more about Aurinia Pharmaceuticals.
CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions. Learn more about CareDx.
Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Learn more about Novartis.
Pentec Health compounds patient specific, Intra
dialytic Parenteral Nutrition (IDPN) and Intraperitoneal Nutrition (IPN) therapies that are custom prepared to meet the individual needs of each patient. Over the past three decades, we have earned the trust of nephrologists nationwide through our therapy that supports nutritional needs for patients who exhibit protein malnutrition. Learn more at Pentec Health.
Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. We are focused on developing medicines that will change treatment paradigms. Today, we have more than 400 employees united by a passion for improving people’s lives. Our unique technology platform includes a proprietary high-throughput chemistry process, enabling us to efficiently explore thousands of potential polymer medicines for each disease we seek to address. Learn more about Relypsa.
CVS Kidney Care understands that for those living with chronic kidney disease or end-stage renal disease, care and treatment needs do not start nor stop with dialysis.
We’re providing patient-centered care by helping people make personal and confident treatment decisions to help improve their health and quality of life. Learn more about CVS Kidney Care.
Humacyte®, Inc., a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte has created a first-in-class, bioengineered tissue, HUMACYL®. HUMACYL® is currently being investigated in clinical trials as a conduit for vascular access but has the potential for multiple vascular and non-vascular applications. Learn more about Humacyte.
Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. Our mission is to change the management of disease worldwide by using information gained from a simple blood draw to proactively inform treatment. Learn more about Natera.
pulseData is on a mission to eliminate predictable and preventable sickness. Health systems use our artificial intelligence and machine learning products to predict the future, targeting care efforts to improve outcomes patients at risk of acute events. Learn more about pulseData.
The Rogosin Institute provides the best health care and quality of life for people with kidney disease and its associated conditions and conducts clinical and basic research for new treatments. It emphasizes kidney disease prevention and wellness promotion, as well as better public policy for optimal, cost-effective care. Learn more about The Rogosin Institute.
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Learn more about Sangamo Therapeutics.